The influence of neuronal plasticity on the olfaction in the transgenic rat model for Huntington disease investigated with in vivo MRI.
Methodological aspects of in vivo imaging of mutant huntingtin in a mouse model of Huntington's disease.
Longitudinal measurement of synaptic density to monitor progression of Parkinson's disease and Huntington's disease
Preclinical PET imaging of allele-selective mHTT lowering as candidate treatment for Huntington's Disease.
In vivo cerebral imaging of mutant Huntingtin aggregates using ¹¹C-CHDI-180R PET in a nonhuman primate model of Huntington disease
¹H NMR based metabolomics of CSF and blood serum: a metabolic profile for a transgenic rat model of Huntington disease
The phosphodiesterase 10 positron emission tomography tracer, [$^{18}F$]MNI-659, as a novel biomarker for early Huntington disease
3-(Benzylamino)-4-(cyclohexylamino)-n-(2-(piperazin-1-yl)ethyl)benzenesulfonamide derivatives and related ferrostatin-1 analogues as cell death inhibitors for treating e.g. Stroke
3-(benzylamino)-4-(cyclohexylamino)-n-(2-(piperazin-1-yl)ethyl)benzenesulfonamide derivatives and related ferrostatin-1 analogues as cell death inhibitors for treating e.G. stroke